Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors

A compound of formula (I):

• wherein:
• A is N or C(H);
• B is aryl or heteroaryl;
• each R1 is independently selected from R5, halogen, —CF3, —CN, —OR5, —OCF3, —NR5R6,—COOR5, tetrazolyl, —SO3H, —B(OH)2, —CONR5R6, —COR5, —SR5, —SOR5, —SO2R5, —SO2NR5R6, —NR5COR6, —NR5SO2R6 or —OCOR5;
• n1 is 1,2 or 3;
• each R2 is independently selected from R5, halogen, —CF3, —CN, —OR5, —OCF3, —NR5R6, —COOR5, —CONR5R6, —COR5, —SR5, —SOR5, —SO2R5, SO2NR5R6, —NR5COR6, —NR5SO2R6, or —OCOR5;
• n2 is 1, 2 or 3;
• R3 is a -L-R7 group, wherein:
• L is a bond or C1-C4 alkylene, wherein one or more —CH2— units comprised in said alkylene are each optionally replaced by a group independently selected from —O—,—NR5—, —CO—, —S—, —SO—, or —SO2—;
• and
• R7 is selected from hydrogen, halogen, —CF3, —CN, an optionally substituted C1-C4 alkyl, an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, or an optionally substituted heteroaryl, wherein said C1-C4 alkyl, said cycloalkyl, said heterocycloalkyl, said aryl or said heteroaryl is optionally substituted with one or more groups independently selected from R5, halogen, —CF3, —CN, —NR5R6, —CONR5R6, —COR5, —OR5, —SR5, —SOR5, —SO2R5, —SO2N R5R6, —NR5COR6, —NR5SO2R6, —OCOR5, —COOR5, tetrazolyl, —SO3H, or —B(OH)2;
• R4 is selected from an optionally substituted C1-C4 alkyl, an optionally substituted cycloalkyl, or an optionally substituted heterocycloalkyl, wherein said C1-C4 alkyl is optionally substituted with one or more groups independently selected from cycloalkyl, halogen, —CF3, —CN, —OH or —O(C1-C4 alkyl), and further wherein said cycloalkyl or said heterocycloalkyl is optionally substituted with one or more groups independently selected from C1-C4 alkyl, cycloalkyl, halogen, —CF3, —CN, —OH or —O(C1-C4 alkyl);
• and
• each R5 and each R6 is independently selected from hydrogen, an optionally substituted C1-C4 alkyl, an optionally substituted cycloalkyl, or an optionally substituted heterocycloalkyl, wherein said C1-C4 alkyl is optionally substituted with one or more groups independently selected from halogen, —CF3, —CN, —OH, —O(C1-C4 alkyl), —NH2, —NH(C1-C4 alkyl) or —N(C1-C4 alkyl)(C1-C4 alkyl), and further wherein said cycloalkyl and said heterocycloalkyl are each optionally substituted with one or more groups independently selected from C1-C4 alkyl, halogen, —CF3, —CN, —OH, —O(C1-C4 alkyl), —NH2, —NH(C1-C4 alkyl) or —N(C1-C4 alkyl)(C1-C4 alkyl);
• or a pharmaceutically acceptable salt, solvate or prodrug thereof.